Table 1.
Baseline characteristics and stimulation outcome.
| Variable | GnRHa (OPU + 6) | Control | P value |
|---|---|---|---|
| Patients, n | 165 | 163 | |
| Age (years) | 31.7 ± 3.6 | 32.1 ± 4.1 | NS |
| Body mass index (kg/m2) | 27.8 ± 4.8 | 28.2 ± 4.5 | NS |
| Duration of follicle-stimulating hormone (FSH) stimulation (days) | 9.1 ± 1.2 | 9.3 ± 1.1 | NS |
| Total dose of FSH (IU) | 1,831.1 ± 317.0 | 1,844.3 ± 294.7 | NS |
| Total dose of antagonist (mg) | 0.9 ± 0.2 | 1.0 ± 0.2 | NS |
| Endometrium (mm) | 10.7 ± 1.4 | 10.3 ± 1.5 | NS |
| Follicles the day of triggering, n | 12.2 ± 5.8 | 13.5 ± 6.4 | NS |
| Oocytes, n | 9.0 ± 4.5 | 9.9 ± 5.4 | NS |
| MII oocytes, n | 7.2 ± 3.8 | 8.1 ± 4.8 | NS |
| 2PN zygotes, n | 5.4 ± 2.8 | 6.1 ± 3.7 | NS |
| Embryos, n | 5.1 ± 2.8 | 5.7 ± 3.4 | NS |
| Transferred embryos, n | 2.3 ± 0.5 | 2.4 ± 0.8 | NS |
| Vitrified embryos, n | 0.7 ± 1.6 | 0.9 ± 1.8 | NS |
Values are means ± SD. NS = Not significant.
GnRHa, gonadotropin-releasing hormone agonist; MII, metaphase II; PN, pro-nuclei.